In a recent retrospective analysis of the FLAURA trial, the C797S mutation in EGFR exon 20, which occurs at a frequency of 7% when axitinib was used as first-line therapy and accounts for 10–26% of cases of resistance to second-line axitinib therapy, was examined for the mechanisms of acquired resistance to first-line osimertinib in advanced NSCLC with EGFR mutations [93]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.